Frontiers in Pharmacology · Nov 17, 2026

Phytoestrogens in the prevention and treatment of postmenopausal osteoporosis: molecular mechanisms, therapeutic evidence, and traditional Chinese medicine applications

By Li H, Xin L, Han X et al.

Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency-related uncoupling of bone remodeling, with progressive bone loss and fracture susceptibility. We conducted a structured narrative review using searches of PubMed/MEDLINE, Web of Science Core Collection, Scopus, and China National Knowledge Infrastructure from inception to 27 August 2026. We evaluated cell and animal studies, observational studies, randomized trials, and meta-analyses separately. Established phytoestrogen classes, principally isoflavones, lignans, and coumestans, were distinguished from stilbenes included in broader classification schemes, coumarin-related plant metabolites, other isolated metabolites, botanical extracts, and multi-ingredient traditional Chinese medicine (TCM) preparations. Experimental studies support selected metabolite-specific effects on estrogen receptor, bone-remodeling, inflammatory, and redox pathways. Evidence for other proposed pathways and microbiota-mediated effects remains scarce or model-dependent. Human studies are heterogeneous and often involve generally healthy, early postmenopausal, or osteopenic women rather than patients with established PMO who are at high fracture risk. A 2024 meta-analysis of 63 randomized controlled trials (9,026 participants) found modest gains versus placebo at the lumbar spine (mean difference: 0.0175 g/cm ² ; 95% confidence interval: 0.0088–0.0263) and femoral neck (mean difference: 0.0172 g/cm ² ; 95% confidence interval: 0.0046–0.0298). These changes in bone mineral density (BMD) are surrogate outcomes and do not establish antifracture efficacy. Evidence for TCM-related isolated metabolites, botanical extracts, and multi-ingredient preparations is predominantly preclinical or limited by incomplete product characterization. Defined phytoestrogen preparations may warrant further study as adjuncts, but current evidence does not support replacing approved osteoporosis treatments.

doi.org/10.3389/fphar.2026.1879143Open accessInterventions

AgingResearch.News